# TLN-372

Source: https://onco.cc/drugs/tln-372/  
OnCo record `tln-372` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TLN-372 is an experimental small molecule pan-KRAS inhibitor from Treeline Biosciences, in phase 1 trials for KRAS-mutant solid tumours.

## Summary

TLN-372 is a small molecule pan-KRAS inhibitor from Treeline Biosciences. Designed to achieve deep and sustained inhibition of KRAS across its mutant forms (pan-KRAS), not only G12C. Its furthest stage is phase 1, for KRAS-mutant solid tumours. ClinicalTrials.gov registers it in one study linked below. Registry NCT07204340 phase 1 recruiting, alone and with cetuximab or pembrolizumab. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: TLN-372
- Modality: Small molecule pan-KRAS inhibitor
- Mechanism: Designed to achieve deep and sustained inhibition of KRAS across its mutant forms (pan-KRAS), not only G12C.

## Sources

- Treeline Biosciences: treeline.bio: https://treeline.bio/medicines
- Treeline Biosciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07204340
- ClinicalTrials.gov: trials of TLN-372: https://clinicaltrials.gov/search?intr=TLN-372

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Treeline Biosciences](https://onco.cc/companies/treeline-biosciences/)
- trials: [TLN-372 in Advanced KRAS Mutant Solid Tumors](https://onco.cc/trials/nct07204340/)

---
JSON: https://onco.cc/api/v1/entities/tln-372.json